$SLG

SL GREEN REALTY CORP (SLG): Results of Operations and Financial Condition

SL GREEN REALTY CORP (SLG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 a26q2supplemental.htm EX-99.2 Document SL Green Realty Corp., Manhattan's largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing the value of Manhattan commercial properties.

Original reporting
Published Jul 23, 2026, 5:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 23, 2026, 5:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$SLG
Neutral
low confidence
Mentioned
$SLG
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SLGNeutralLow
01

Why it matters

The excerpt does not include the actual financial results, but the supplemental package may contain updated balance-sheet, FFO/FAD computations, leasing statistics, and debt/derivative schedules that can affect valuation and risk perception.

02

Market read

This is a primary-source update that could matter if the omitted tables contain new Q2 results, leasing metrics, or financing/derivative changes.

03

What to watch

Traders should verify the actual EX-99.2 tables for any new FFO/FFO per share, occupancy, leasing spreads, debt/derivative changes, or covenant/financing updates, which could materially change the trading view.

Relevance 7/10Novelty 3/10Timing: Filed July 23, 2026, ahead of the Q2 2026 10-Q due on or before Aug 10, 2026.

Background

The filing is an SEC Form 8-K (Item 2.02) furnishing supplemental information for SL Green’s quarter ended June 30, 2026, to be read with the forthcoming 10-Q.

Company-level read

Ticker impact

$SLGNeutralLow confidence
Context

SL Green filed an 8-K with Item 2.02 and supplemental Q2 2026 financial-condition materials for the quarter ended June 30, 2026.

Expected impact

Near-term price impact is likely limited unless the supplemental package contains new, specific financial results or guidance details beyond what the market already expects.

Evidence & confidence

The provided text is largely boilerplate and table-of-contents/definitions, with no specific earnings numbers, guidance, or balance-sheet deltas included in the excerpt.

Market effects

Limited from the excerpt; any read-across would depend on office-REIT leasing/FFO trends that are not shown here.

Limited from the excerpt; Manhattan office landlord specifics are referenced but no new leasing/occupancy metrics are included.

Low, since this is a single-company filing without disclosed macro or cross-border developments in the excerpt.

Counterpoint

Because the excerpt contains mostly definitions and document structure, the market may already be positioned for the upcoming 10-Q, making this filing more of a formality than a catalyst.

Key entities

  • SL Green Realty Corp.

    Manhattan-focused office REIT filing an 8-K with supplemental Q2 2026 financial-condition materials.

Related articles

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

$KDPMed

Keurig Dr Pepper Inc. Q2 2026 Earnings Call Summary

Keurig Dr Pepper reported Q2 2026 results that exceeded expectations, citing double-digit U.S. Refreshment Beverages growth and day-one integration of JDE Peet's. Dr Pepper Zero Sugar grew 30% in retail sales and energy reached 9% market share. U.S. Coffee faced margin pressure from hedging and tariffs. KDP reaffirmed low double-digit EPS growth for 2026 and low-double-digit legacy growth at the high end of 4% to 6%.

$TAPMed

Molson Coors Beverage Company Q2 2026 Earnings Call Summary

Molson Coors reported Q2 2026 volume pressure tied to an energy and inflation shock after conflict in Iran, plus stronger promotions and geopolitical uncertainty in EMEA and APAC. The company reaffirmed FY2026 guidance, citing improving U.S. industry volumes, 1% to 2% annual U.S. price increases, and Midwest Premium aluminum COGS above $130 million, partly hedged. It also outlined a $450 million cost-savings plan and Atomic Brands integration.